Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Singapore Patent Office has granted a patent to Genprex that covers the use of the Company’s lead drug candidate, Reqorsa® Gene Therapy, in combination with anti-PD-1 antibodies through 2037.

This patent expands on the previously granted patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China and Korea to cover the use of REQORSA in combination with an immune checkpoint inhibitor, i.e., PD-1 antibodies. The granted Korean patent also claims the use of REQORSA in combination with PD-L1 antibodies. Genprex will be pursuing additional patent applications with claims to combinations of REQORSA and PD-L1 antibodies in the US, Brazil, Canada, China, Europe and Israel. Should these applications grant, they would be applicable to Genprex’s Acclaim-3 clinical trial.

PD-1 inhibitors and PD-L1 inhibitors are a type of targeted immunotherapy and a part of a group of checkpoint inhibitor anti-cancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells.

“This patent expands our intellectual property portfolio, providing us with additional protection and exclusivity for our drug combinations with REQORSA and furthering our patent protection in the Asian markets where lung cancer is the most prevalent,” said Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex.

According to GLOBOCAN, in 2022 Asia accounted for 63% of new lung cancer cases worldwide, which is equal to more than 1.5 million new cases of lung cancer per year. In 2022, China alone had more than 1 million new cases of lung cancer.

The Acclaim-3 study is a Phase 1/2 clinical trial that uses a combination of REQORSA and Genentech’s Tecentriq® as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) who developed tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. The Acclaim-3 clinical trial has received U.S. Food and Drug Administration (FDA) Fast Track Designation for this patient population, and Acclaim-3 has received FDA Orphan Drug Designation.

 

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company’s lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is currently being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex’s lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Source:
https://www.prnewswire.com/news-releases/genprex-granted-patent-in-singapore-for-reqorsa-gene-therapy-with-pd-1-antibodies-to-treat-cancers-302220830.html
GMP mRNA
Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE